investor.myriad.comInvestor FAQs | Myriad Genetics, Inc.

Skip to main navigation You are using an outdated browser. Please upgrade your browser to improve your experience. Myriad Sites Myriad International Myriad RBM Myriad Worldwide Investors Products & Services All Products Overview Breast Cancer EndoPredict ® Carrier Screen Foresight ® Depression GeneSight ® Hereditary Cancers Myriad myRisk ® Hereditary Cancer riskScore ® BRAC Analysis ® COLARIS ® COLARIS AP ® Melanoma Myriad myPath ® Melanoma Precision Medicine BRACAnalysis CDx ® myChoice ® HRD Prenatal Screen Prequel TM Prostate Cancer Prolaris ® Rheumatoid Arthritis Vectra ® Contact Us Corporate Offices International Offices Menu Toggle navigation Myriad Sites Myriad International Myriad RBM Myriad Worldwide Investors Products & Services All Products Overview Breast Cancer EndoPredict ® Carrier Screen Foresight ® Depression GeneSight ® Hereditary Cancers Myriad myRisk ® Hereditary Cancer riskScore ® BRAC Analysis ® COLARIS ® COLARIS AP ® Melanoma Myriad myPath ® Melanoma Precision Medicine BRACAnalysis CDx ® myChoice ® HRD Prenatal Screen Prequel TM Prostate Cancer Prolaris ® Rheumatoid Arthritis Vectra ® Contact Us Corporate Offices International Offices Patients and Families Disease Info Carrier Screen Depression Hereditary Breast Cancer Hereditary Colon Cancer Hereditary Endometrial Cancer Melanoma Hereditary Ovarian Cancer Hereditary Pancreatic Cancer Prenatal Screen Prostate Cancer Rheumatoid Arthritis Your Questions About Disease What’s My Risk? Do I Have a Disease? How Aggressive is My Disease? How Should I Treat My Disease? Learn About the Quiz Genetic Testing 101 Genes & Disease Benefits of Genetic Testing Genetic Testing FAQs The Myriad Advantage View Product Details The Myriad Difference The Myriad Promise Financial Assistance Program Customer Service Your Privacy Patient Resources mySupport360™ Hereditary Cancer Quiz Real Patient Stories Patient Support Groups Find a Healthcare Provider Healthcare Professionals Disease Education Carrier Screen Depression Hereditary Breast Cancer Hereditary Colon Cancer Hereditary Endometrial Cancer Melanoma Hereditary Ovarian Cancer Hereditary Pancreatic Cancer Prenatal Screen Prostate Cancer Rheumatoid Arthritis Improving Patient Care Predicting Disease Diagnosing Disease Assessing Prognosis Guiding Personalized Treatment Learn More About Genetic Testing Genetic Testing Process Genetic Tests for Hereditary Cancers Genetic Testing FAQs Policy on Genetic Information Financial Assistance Program View Product Details Professional Resources MyriadPro Hereditary Cancer Quiz Order a Test Kit Myriad Lab Certificates Order a Test Kit Need Help? Myriad Customer Service 800-4-MYRIAD (800-469-7423) (801) 584-1175 cscomments@myriad.com Learn About the Quiz Insurance Providers Myriad Managed Care Decrease costs while improving patient well-being Learn More » Lab Accuracy Accurate test results drive optimal treatments myVision ® » Databases » Accreditations » Myriad Products Myriad myRisk ® Hereditary Cancer » Prolaris ® Prostate Cancer » GeneSight ® Mental Illness » EndoPredict ® Breast Cancer » Vectra ® Rheumatoid Arthritis » BRACAnalysis CDx ® Ovarian and Metastatic Breast Cancers » Myriad myPath ® Melanoma » Contact Us Today If you are a payer or insurance provider, please contact us to receive more information. Research Partnerships Research at Myriad View Myriad Pipeline Partnerships & Licensing Companion Diagnostics Partnerships Other Industry Partnerships Licensing at Myriad Academic Collaborations Interested in Collaborating with Myriad? Contact: Sam LaBrie Senior Vice President, Corporate Development Myriad Genetics, Inc. (512)225-9287 slabrie@myriad.com News Center Media Newsroom Executive Bios News Releases Events & Presentations Ron Rogers EVP, Corporate Communications (801) 584-3065 rrogers@myriad.com Investor Information Investor FAQs News Releases Events & Presentations Financial Reporting Stock Information Scott Gleason VP, Investor Relations (801) 584-1143 sgleason@myriad.com Multimedia Library Videos Infographics Images View Infographic Myriad Matters Blog What You Need to Know About Hereditary Colon Cancer Video – Pioneering Advances in Personalized Medicine Corporate Fact Sheet Careers at Myriad The Myriad Culture Our Employees Our Community Our Diversity Video – 2012 RAGNAR Race Joining the Myriad Team Current Openings Internships Employment Benefits Myriad Fact Sheet About Myriad Inside Myriad Business Units Myriad At-A-Glance Company Fact Sheet History Executive Bios Board of Directors Company Milestones Myriad Around the World Global Presence International Distributors International Distributor Map Locations & Directions Directions to Myriad Directions to Myriad Autoimmune Directions to Myriad Neuroscience Directions to Myriad International Directions to Myriad RBM Myriad Cares The Myriad Pledge The Myriad Promise Corporate Social Responsibility Financial Assistance Program Patient Advocacy Patient Support Groups Policy on Genetic Information Contact Us 800 4-MYRIAD (800 469-7423) Myriad Genetics, Inc. 320 Wakara Way Salt Lake City, UT 84108 Corporate Fact Sheet Investor Information Investor Relations Understanding Myriad Investor FAQs Corporate Governance Executive Bios Board of Directors News Releases All Financial News Corporate News Product News Pipeline News Events & Presentations Financial Events Scientific Events Financial Reporting GAAP to Non-GAAP Reconciliation Latest Earnings Release SEC Filings Quarterly & Annual Reports Archived Annual Reports Key Ratios Stock Information Historic Stock Lookup Investment Calculator Dividend History Request Information Investor FAQs Show All When was Myriad Genetics Founded? Myriad Genetics was founded in May 1991. Where are your corporate headquarters? Our corporate headquarters and all our facilities are located at 320 Wakara Way, Salt Lake City, Utah When did Myriad Genetics become a public company? We completed our initial public offering in October 1995. What is Myriad Genetics' CUSIP number? Our CUSIP number is 62855J104. What is your stock symbol? Our common stock is listed on the Nasdaq Global Select Market under the symbol "MYGN." How can I buy Myriad Genetics stock? You may purchase our stock through a registered stock broker, bank or through a financial institution that provides brokerage services. Myriad Genetics does not offer a direct purchase plan for investors. What is the fiscal year for Myriad Genetics? Our fiscal year ends on June 30. When do Myriad Genetics' fiscal quarters end? First quarter – September 30 Second quarter – December 31 Third quarter – March 31 Fourth quarter – June 30 Who is Myriad Genetics' transfer agent? Our transfer agent is American Stock Transfer & Trust Company. They are responsible for maintaining all records of registered shareholders (including change of address and name), cancelling or issuing stock certificates and resolving problems related to lost, destroyed or stolen certificates. If your shares are held in Street name, you will have to contact your broker for these services. You may contact our transfer agent at: American Stock Transfer & Trust Company 59 Maiden Lane New York, New York 10038 (800) 937-5449 (718) 921-8124 www.amstock.com Who should I contact for information about my shareholder account? If you have questions about your shareholder account you should contact our transfer agent, American Stock Transfer & Trust Company at (800) 937-5499. How do I contact Myriad Genetics' investor relations department? Please contact Scott Gleason, Investor Relations, at: 801-584-1143 sgleason@myriad.com Introducing riskScore™: A groundbreaking breast cancer risk-prediction tool Stock Quote Stock Quote Intraday High: 52 Week High: Intraday Low: 52 Week Low: Volume Data Provided by Refinitiv. Minimum 15 minutes delayed. Personalizing Prostate Cancer Treatment Prolaris measures cancer aggressiveness to help personalize treatment for men with prostate canc...